Scott Bowden

Summary

Affiliation: Royal Melbourne Hospital
Country: Australia

Publications

  1. ncbi Hepatitis B: the case for combination therapy
    Scott Bowden
    Victorian Infectious Diseases Reference Laboratory, 10 Wreckyn Street, North Melbourne, Victoria 3051, Australia
    Curr Opin Investig Drugs 10:795-803. 2009
  2. ncbi New hepatitis viruses: contenders and pretenders
    S Bowden
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Australia
    J Gastroenterol Hepatol 16:124-31. 2001
  3. ncbi New developments in HBV molecular diagnostics and quantitative serology
    D Scott Bowden
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Vic, Australia
    Hepatol Int 2:3-11. 2008
  4. ncbi Chronic hepatitis C virus infection: genotyping and its clinical role
    D Scott Bowden
    Victorian Infectious Diseases Reference Laboratory, and Department of Microbiology, Monash University, Clayton, Carlton South, Victoria, Australia
    Future Microbiol 1:103-12. 2006
  5. ncbi Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia
    Tin Nguyen
    Department of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, North Melbourne, Vic, Australia
    J Hepatol 52:508-13. 2010
  6. ncbi Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis
    Stuart Roberts
    Department of Gastroenterology, Alfred Hospital, Melbourne, Victoria, Australia
    Clin Gastroenterol Hepatol 5:932-7. 2007
  7. ncbi Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers
    Alexander J V Thompson
    Department of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
    Hepatology 51:1933-44. 2010
  8. ncbi Drug resistance in antiviral therapy
    Stephen Locarnini
    Department of R and MD, North Melbourne, Victoria, Australia
    Clin Liver Dis 14:439-59. 2010
  9. ncbi Comparison of sequence analysis and a novel discriminatory real-time PCR assay for detection and quantification of Lamivudine-resistant hepatitis B virus strains
    Fiona Wightman
    Department of Medicine, Monash University, Melbourne, Australia
    J Clin Microbiol 42:3809-12. 2004
  10. ncbi Coinfection of hepatic cell lines with human immunodeficiency virus and hepatitis B virus leads to an increase in intracellular hepatitis B surface antigen
    David M Iser
    Department of Medicine, University of Melbourne, St Vincent s Hospital, Melbourne, Victoria, Australia
    J Virol 84:5860-7. 2010

Collaborators

Detail Information

Publications24

  1. ncbi Hepatitis B: the case for combination therapy
    Scott Bowden
    Victorian Infectious Diseases Reference Laboratory, 10 Wreckyn Street, North Melbourne, Victoria 3051, Australia
    Curr Opin Investig Drugs 10:795-803. 2009
    ....
  2. ncbi New hepatitis viruses: contenders and pretenders
    S Bowden
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Australia
    J Gastroenterol Hepatol 16:124-31. 2001
    ..However, the lessons learnt from the hepatitis virus pretenders will need to be applied to SEN-V and any future contenders...
  3. ncbi New developments in HBV molecular diagnostics and quantitative serology
    D Scott Bowden
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Vic, Australia
    Hepatol Int 2:3-11. 2008
    ..A wide variety of research techniques are being used to investigate chronic hepatitis B. Further evaluation is needed to decide which will have the greatest clinical applicability...
  4. ncbi Chronic hepatitis C virus infection: genotyping and its clinical role
    D Scott Bowden
    Victorian Infectious Diseases Reference Laboratory, and Department of Microbiology, Monash University, Clayton, Carlton South, Victoria, Australia
    Future Microbiol 1:103-12. 2006
    ..The molecular basis for the differences in response of HCV genotypes has yet to be determined...
  5. ncbi Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia
    Tin Nguyen
    Department of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, North Melbourne, Vic, Australia
    J Hepatol 52:508-13. 2010
    ..We aimed to define the serum HBsAg titres during the different phases of CHB in a cohort of Asian patients infected with either genotype B or C HBV...
  6. ncbi Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis
    Stuart Roberts
    Department of Gastroenterology, Alfred Hospital, Melbourne, Victoria, Australia
    Clin Gastroenterol Hepatol 5:932-7. 2007
    ..The aims of this study were to investigate the effect of treatment with peginterferon alfa-2a and ribavirin on hepatic venous pressure gradient (HVPG) in CHC with compensated cirrhosis...
  7. ncbi Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers
    Alexander J V Thompson
    Department of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
    Hepatology 51:1933-44. 2010
    ..These findings provide new insights into viral pathogenesis and have practical implications for the use of quantitative serology as a clinical biomarker...
  8. ncbi Drug resistance in antiviral therapy
    Stephen Locarnini
    Department of R and MD, North Melbourne, Victoria, Australia
    Clin Liver Dis 14:439-59. 2010
    ....
  9. ncbi Comparison of sequence analysis and a novel discriminatory real-time PCR assay for detection and quantification of Lamivudine-resistant hepatitis B virus strains
    Fiona Wightman
    Department of Medicine, Monash University, Melbourne, Australia
    J Clin Microbiol 42:3809-12. 2004
    ..Excellent concordance was demonstrated between sequencing and the discriminatory real-time assay; however, a mixture of quasispecies was more frequently detected by discriminatory real-time PCR...
  10. ncbi Coinfection of hepatic cell lines with human immunodeficiency virus and hepatitis B virus leads to an increase in intracellular hepatitis B surface antigen
    David M Iser
    Department of Medicine, University of Melbourne, St Vincent s Hospital, Melbourne, Victoria, Australia
    J Virol 84:5860-7. 2010
    ....
  11. ncbi Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro
    Robert Y m Chen
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
    Hepatology 37:27-35. 2003
    ..In conclusion, the PC stop codon mutation appears to increase the replication efficacy of lamivudine-resistant virus but does not affect in vitro drug sensitivity...
  12. ncbi Lamivudine resistant occult HBV: implications for public health?
    Scott Bowden
    Victorian Infectious Diseases Reference Laboratory, 10 Wreckyn Street, North Melbourne, Vic. 3051, Australia
    J Hepatol 38:526-8. 2003
  13. ncbi Decreased viral load and symptoms of polyomavirus-associated chronic interstitial cystitis after intravesical cidofovir treatment
    Damon P Eisen
    Victorian Infectious Diseases Service, Royal Melbourne Hospital, Parkville, Australia
    Clin Infect Dis 48:e86-8. 2009
    ..Another patient had milder symptoms of cystitis and intermittent polyomavirus shedding. Polyomaviruses, particularly BK virus, may cause some cases of interstitial cystitis...
  14. ncbi A study to investigate the impact of the initiation of highly active antiretroviral therapy on the hepatitis C virus viral load in HIV/HCV-coinfected patients
    Anne Mijch
    Department of Infectious Diseases, Alfred Hospital, Melbourne, Victoria, Australia
    Antivir Ther 10:277-84. 2005
    ..The increase in the HCV VL was not associated with hepatitis as determined by raised alanine transferase...
  15. ncbi TCD8 response in diverse outcomes of recurrent exposure to hepatitis C virus
    Mandvi Bharadwaj
    Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia
    Immunol Cell Biol 87:464-72. 2009
    ....
  16. ncbi Serological and molecular diagnosis
    Scott Bowden
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
    Semin Liver Dis 26:97-103. 2006
    ....
  17. ncbi Quantification of HBV covalently closed circular DNA from liver tissue by real-time PCR
    Scott Bowden
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Australia
    Methods Mol Med 95:41-50. 2004
  18. ncbi Characterisation of single nucleotide polymorphisms in the genome of JC polyomavirus using MALDI TOF mass spectrometry
    Julianne Bayliss
    Department of Medicine, Monash University, Alfred Hospital, Victoria, Australia
    J Virol Methods 164:63-7. 2010
    ..MALDI TOF MS identified eight novel SNPs in the VP1 gene. This study represents the first application of MALDI TOF MS to viral comparative sequence analysis...
  19. ncbi Molecular epidemiology of hepatitis C virus in a social network of injection drug users
    Campbell K Aitken
    Epidemiology and Social Research Program, Melbourne, Victoria, Australia
    J Infect Dis 190:1586-95. 2004
    ..We aimed to measure the overlap between the social networks of injection drug users (IDUs) and the patterns of related hepatitis C virus (HCV) infections among IDUs...
  20. ncbi Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C
    Adam Gordon
    Department of Gastroenterology, The Alfred Hospital, Victoria, Australia
    J Gastroenterol Hepatol 21:275-80. 2006
    ..CONCLUSIONS: S. marianum is well tolerated in subjects with CHC, but does significantly affect serum HCV RNA, alanine aminotransferase levels, quality of life or psychological well-being in subjects with this condition...
  21. ncbi GB virus C genotype 2 predominance in a hepatitis C virus/HIV infected population associated with reduced liver disease
    Mark D Berzsenyi
    Department of Gastroenterology, Alfred Hospital, Prahran, Victoria, Australia
    J Gastroenterol Hepatol 24:1407-10. 2009
    ..The aim of the present study was to identify the GBV-C genotype in a HCV/HIV co-infected population and determine if the GBV-C genotype contributes to a reduction in HCV-related liver disease...
  22. ncbi GB virus C: insights into co-infection
    Mark D Berzsenyi
    Department of Gastroenterology, Alfred Hospital, Commercial Road, Prahran 3181, Victoria, Australia
    J Clin Virol 33:257-66. 2005
    ..Elucidation of the putative protective effect of GBV-C in HIV co-infection could potentially identify novel targets for anti-HIV therapeutics and lead to the development of disease modifying vaccines...
  23. ncbi Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors
    Alexander J V Thompson
    St Vincent s Hospital, Melbourne, Victoria, Australia
    J Gastroenterol Hepatol 22:1078-85. 2007
    ..The present study was designed to identify factors predictive of lamivudine resistance, with a particular focus on the role of precore and basal core promoter variants in the setting of hepatitis B e antigen-negative disease...
  24. ncbi Serum alanine aminotransferase levels and the detection of hepatitis C virus (HCV) in chronic HCV infections
    Heath A Kelly
    Med J Aust 176:139. 2002